Oseini, Abdul M.
Cole, Banumathi K.
Issa, Danny
Feaver, Ryan E.
Sanyal, Arun J.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK007150/DK/NIDDK)
HemoShear Therapeutics (R44 DK115301)
National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK105961/DK/NIDDK)
Article History
Received: 14 August 2017
Accepted: 24 November 2017
First Online: 3 January 2018
Compliance with ethical standards
:
: Abdul M. Oseini, MD No conflicts to disclose, Danny Issa, MD No conflicts to disclose, Ryan E. Feaver, PhD Employee of HemoShear, Banumathi K. Cole, PhD Employee of HemoShear. Dr. Sanyal is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect, Exhalenz and Hemoshear. He has served as a consultant to AbbVie, Astra Zeneca, Nitto Denko, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Fibrogen, Jannsen, Gilead, Boehringer, Lilly, Zafgen, Novartis, Pfizer, Jannsen and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Novo Nordisk, Affimune, Chemomab, Nordic Bioscience and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Novartis. He receives royalties from Elsevier and UptoDate.